Alpha Tau Medical’s glioblastoma milestone and what it means for investors

Alpha Tau Medical (NasdaqCM:DRTS) has attracted fresh investor attention after reporting the first successful Alpha DaRT treatment of a recurrent glioblastoma patient in Israel, and the first outside the United States.

The procedure used the company’s brain specific delivery system at Hadassah University Medical Center in Jerusalem, targeting a recurrent tumor via a minimally invasive burr hole while maintaining real time stereotactic neuro navigation.

Alpha Tau Medical’s latest glioblastoma update lands after a period of strong momentum, with a 90 day share price return of 62.83% and a 1 year total shareholder return of 270.48%. This suggests that sentiment around future prospects has shifted meaningfully.

If this breakthrough has you looking beyond a single stock, it could be a good moment to scan other healthcare focused AI opportunities using our 39 healthcare AI stocks.

With Alpha Tau Medical’s stock up sharply over the past year and sitting about 27% below one analyst price target, the key question is whether recent gains leave more room on the table or if markets already reflect expectations for future growth.

Preferred Price to Book multiple of 14.5x: Is it justified?

On the latest data, Alpha Tau Medical trades on a P/B of 14.5x, which puts the $11.17 share price well above typical valuation levels for its sector and peers.

The P/B multiple compares the company’s market value to its book value, giving a rough sense of how much investors are willing to pay for each dollar of net assets. For a clinical stage oncology company that is still loss making, a high P/B often reflects expectations for future revenue growth and successful commercialization rather than current financial results.

In this case, the premium is clear. Alpha Tau Medical’s 14.5x P/B is significantly higher than the US Medical Equipment industry average of 2.5x and also well above the peer average of 1.6x, which points to much stronger expectations being priced in than those implied for many competitors.

Result: Price-to-book of 14.5x (OVERVALUED)

However, investors also need to weigh clinical and regulatory uncertainty around Alpha Tau Medical’s Alpha DaRT platform, along with continued losses and zero reported revenue to date.

Next Steps

With sentiment on Alpha Tau Medical clearly split between its glioblastoma progress and a rich valuation, this is a moment to look at the numbers yourself and move quickly to form your own view using the 1 key reward and 4 important warning signs.

Looking for more Alpha Tau Medical style investment ideas?

If Alpha Tau Medical has sharpened your focus on stock selection, do not stop here. Broaden your watchlist with other focused ideas that might suit your approach.

• Target potential value opportunities by checking companies highlighted in the 43 high quality undervalued stocks.
• Prioritise resilience by reviewing the 67 resilient stocks with low risk scores and see which stocks score well on risk metrics.
• Hunt for underfollowed opportunities with the screener containing 19 high quality undiscovered gems and see which stocks stand out on fundamentals before they hit the spotlight.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.